Caribou Biosciences, Inc. Investing Cash Flow
Caribou Biosciences, Inc. (CRBU) reported Investing Cash Flow of $42.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $18.94M, a 21.19% decline year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $23.98M, a 51.43% decline year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $17.97M, a 12.81% increase year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $10.85M, a 59.09% decline year-over-year.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $102.24M, a 18.05% increase from fiscal 2024.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $86.61M.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$68.18M.
- Caribou Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$93.25M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $42.93M 10-Q · filed 2026-08-13 | $60.90M derived: sum of 3 quarters · filed 2026-08-13 | $71.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $23.98M 10-Q · filed 2026-05-07 | $41.95M derived: sum of 2 quarters · filed 2026-05-07 | $52.81M derived: sum of 3 quarters · filed 2026-05-07 | $76.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $17.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.82M derived: sum of 2 quarters · filed 2026-03-05 | $52.86M derived: sum of 3 quarters · filed 2026-08-13 | $102.24M 10-K · filed 2026-03-05 |
| 2025-09-30 | $10.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $34.89M derived: sum of 2 quarters · filed 2026-08-13 | $84.27M 10-Q · filed 2025-11-12 | $100.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $24.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $73.42M 10-Q · filed 2026-08-13 | $89.35M derived: sum of 3 quarters · filed 2026-08-13 | $115.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $49.38M 10-Q · filed 2026-05-07 | $65.31M derived: sum of 2 quarters · filed 2026-05-07 | $91.83M derived: sum of 3 quarters · filed 2026-05-07 | $113.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $42.45M derived: sum of 2 quarters · filed 2026-03-05 | $63.65M derived: sum of 3 quarters · filed 2026-03-05 | $86.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $26.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $47.72M derived: sum of 2 quarters · filed 2025-11-12 | $70.68M 10-Q · filed 2025-11-12 | $39.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $21.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $44.16M 10-Q · filed 2025-08-12 | $12.68M derived: sum of 3 quarters · filed 2025-08-12 | -$55.79M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $22.96M 10-Q · filed 2025-05-08 | -$8.52M derived: sum of 2 quarters · filed 2025-05-08 | -$76.99M derived: sum of 3 quarters · filed 2025-05-08 | -$65.93M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$31.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$99.95M derived: sum of 2 quarters · filed 2025-03-10 | -$88.89M derived: sum of 3 quarters · filed 2025-03-10 | -$68.18M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$68.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$57.41M derived: sum of 2 quarters · filed 2024-11-06 | -$36.71M 10-Q · filed 2024-11-06 | -$35.54M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $11.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $31.77M 10-Q · filed 2024-08-06 | $32.94M derived: sum of 3 quarters · filed 2024-08-06 | $24.60M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $20.70M 10-Q · filed 2024-05-07 | $21.87M derived: sum of 2 quarters · filed 2024-05-07 | $13.53M derived: sum of 3 quarters · filed 2024-05-07 | -$439.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$7.17M derived: sum of 2 quarters · filed 2024-03-11 | -$21.14M derived: sum of 3 quarters · filed 2024-03-11 | -$93.25M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$8.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$22.31M derived: sum of 2 quarters · filed 2023-11-07 | -$94.42M 10-Q · filed 2023-11-07 | -$268.38M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$13.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$86.08M 10-Q · filed 2023-08-08 | -$260.04M derived: sum of 3 quarters · filed 2023-08-08 | -$261.97M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$72.11M 10-Q · filed 2023-05-09 | -$246.07M derived: sum of 2 quarters · filed 2023-05-09 | -$248.00M derived: sum of 3 quarters · filed 2023-05-09 | -$248.48M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$173.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$175.89M derived: sum of 2 quarters · filed 2023-03-09 | -$176.38M derived: sum of 3 quarters · filed 2023-03-09 | -$176.40M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.41M derived: sum of 2 quarters · filed 2022-11-08 | -$2.44M 10-Q · filed 2022-11-08 | -$3.04M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$484.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$506.00K 10-Q · filed 2022-08-09 | -$1.11M derived: sum of 3 quarters · filed 2022-08-09 | -$1.11M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$22.00K 10-Q · filed 2022-05-09 | -$622.00K derived: sum of 2 quarters · filed 2022-05-09 | -$626.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$604.00K derived: sum of 2 quarters · filed 2022-03-21 | $6.36M 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $6.96M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $6.97M 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $27.23M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |